18F-FDG-PET/CT evaluation of response to treatment in lymphoma: When is the optimal time for the first re-evaluation scan?

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 3, 2008, Pages 153-156

  Iagaru, Andrei ^a   Wang, Yingbing ^a   Mari, Carina ^b   Quon, Andrew ^a   Goris, Michael L ^a   Horning, Sandra ^a   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FDG PET CT; Lymphoma; Re evaluation; Treatment response

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 60849123940     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 6837693.
3. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
4. 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
5. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiblogy 1999; 213: 521-525.
6. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998 30; 17: 2635-2650.
7. la Fougere C, Hundt W, Brockel N et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2006; 33: 1417-1425.
8. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237: 1038-1045.
9. Kazama T, Faria SC, Varavithya V et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005; 25: 191-207.
10. De Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8 (Suppl 1): S57-S60.
11. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using fluorine-18-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
12. Radford JA, Cowan RA, Flanagan M et al. The significance of residual mediastinal abnormality on CXR following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940-946.
13. Hoekstra OS, Ossenkoppele GJ, Golding R et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
14. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523.
15. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59.
16. Kostakoglu L, Coleman M, Leonard JP et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin disease. J Nucl Med 2002; 43: 1018-1027.
17. Davis TA, Horning SJ. Advances in the management of Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Hematol 1998; 5: 259-263.